Cargando…

The thyroid function of Graves' disease patients is aggravated by depressive personality during antithyroid drug treatment

BACKGROUND: We previously reported that depressive personality (the scores of hypochondriasis, depression and psychasthenia determined by the Minnesota Multiphasic Personality Inventory (MMPI)) and daily hassles of Graves' disease (GD) patients treated long trem with antithyroid drug (ATD) were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fukao, Atsushi, Takamatsu, Junta, Kubota, Sumihisa, Miyauchi, Akira, Hanafusa, Toshiaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3174109/ https://www.ncbi.nlm.nih.gov/pubmed/21827669 http://dx.doi.org/10.1186/1751-0759-5-9

Ejemplares similares

Graves’ disease and mental disorders
por: Fukao, Atsushi, et al.
Publicado: (2019)

Antithyroid Drug Treatment in Graves’ Disease
por: Chung, Jae Hoon
Publicado: (2021)

Antithyroid Drug Therapy for Graves' Disease and Implications for Recurrence
por: Liu, Jia, et al.
Publicado: (2017)

Antithyroid drugs in Graves’ disease: Are we stretching it too far?
por: Jayaraman, Muthukrishnan, et al.
Publicado: (2016)

Antithyroid Drugs in the Management of Graves' Disease: A Friend and Foe
por: Butt, Muhammad I, et al.
Publicado: (2023)

Prediction for recurrence following antithyroid drug therapy for Graves’ hyperthyroidism
por: Weng, Huan, et al.
Publicado: (2023)

Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease
por: Kwon, Hyemi, et al.
Publicado: (2016)

Antithyroid arthritis syndrome caused by methimazole in a patient with Graves’ disease
por: Kawasumi, Muneo, et al.
Publicado: (2023)

Indefinite antithyroid drug therapy in toxic Graves’ disease: What are the cons
por: Rajput, Rajesh, et al.
Publicado: (2013)

Risk Factors for Granulocytopenia in Patients with Graves' Disease Receiving Antithyroid Drugs
por: Li, Jiaxi, et al.
Publicado: (2023)

Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy
por: Choi, Yun Mi, et al.
Publicado: (2019)

Early Biochemical Response to Antithyroid Drugs in Graves’ Disease: The Role of Initial Dosing
por: El Kawkgi, Omar M, et al.
Publicado: (2021)

Clinical Features and Remission Rate of Pediatric Graves’ Hyperthyroidism Treated With Antithyroid Drug
por: You, Kyusang, et al.
Publicado: (2021)

Changes in the Ocular Parameters of Patients with Graves’ Disease after Antithyroid Drug Treatment
por: Lee, Je-Sang, et al.
Publicado: (2021)

Long-term outcomes of Graves’ disease in children and adolescents receiving antithyroid drugs
por: Rho, Jung Gi, et al.
Publicado: (2021)

Antithyroid drugs
por: Jastrzębska, Helena
Publicado: (2015)

Antithyroid Drugs
por: Abdi, Hengameh, et al.
Publicado: (2019)

Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves' disease?
por: Belsing, Tina Z, et al.
Publicado: (2010)

Relationship between dose of antithyroid drugs and adverse events in pediatric patients with Graves’ disease
por: Yasuda, Kie, et al.
Publicado: (2017)

Commentary on "Long-term outcomes of Graves’ disease in children and adolescents receiving antithyroid drugs"
por: Kim, Minsun
Publicado: (2021)

Remission in pediatric Graves’ disease treated with antithyroid drug and the risk factors associated with relapse
por: Wong, Tsz Wai Catherine, et al.
Publicado: (2022)

A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice
por: Liu, Xiaomei, et al.
Publicado: (2015)

Predictive Value of Gene Polymorphisms on Recurrence after the Withdrawal of Antithyroid Drugs in Patients with Graves’ Disease
por: Liu, Jia, et al.
Publicado: (2017)

Predictors of Initial and Sustained Remission in Patients Treated with Antithyroid Drugs for Graves' Hyperthyroidism: The RISG Study
por: Karmisholt, J., et al.
Publicado: (2019)

Commentary on “Remission in pediatric Graves’ disease treated with antithyroid drug and the risk factors associated with relapse”
por: Kim, Ji Hyun
Publicado: (2022)

Antithyroid treatment improves thrombocytopenia in a young patient with Graves’ disease
por: Faienza, Maria Felicia, et al.
Publicado: (2020)

A case of antithyroid drug‐induced agranulocytosis from a second antithyroid drugs (ATD) administration in a relapsed Graves' disease patient who was tolerant to the first ATD treatment
por: Kim, Hyunsam, et al.
Publicado: (2018)

Rescue of Graves Thyrotoxicosis-Induced Cholestatic Liver Disease Without Antithyroid Drugs: A Case Report
por: Yan, Lily D., et al.
Publicado: (2017)

MON-621 A Second Course of Antithyroid Drug Therapy Is Effective in Patients with Relapsed Graves' Disease
por: Seejore, Khyatisha, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Antithyroid Drug (Propylthiouracil) Compared to Radioactive Iodine for the Treatment of Graves’ Disease in Ethiopia
por: Mengistu, Habtamu Solomon, et al.
Publicado: (2022)

Long-term follow-up result of antithyroid drug treatment of Graves’ hyperthyroidism in a large cohort
por: Jin, Meihua, et al.
Publicado: (2023)

IMPACT OF GRAVES’ DISEASE AND ANTITHYROID DRUG THERAPY ON BONE MINERAL DENSITY – PATHOPHYSIOLOGICAL MECHANISMS AND CLINICAL RELEVANCE
por: Mudri, Dunja, et al.
Publicado: (2022)

Changes in Glucose Intolerance after Treatment with Antithyroid Drugs in Patients with Graves' Disease Using Continuous Glucose Monitoring: A Pilot Study
por: Kurozumi, Akira, et al.
Publicado: (2022)

Primary immune thrombocytopenia responding to antithyroid treatment in a patient with Graves’ disease
por: Gill, Harinder, et al.
Publicado: (2010)

The Effect of Thyrotropin-Releasing Hormone and Antithyroid Drugs on Fetal Thyroid Function
por: Vrachnis, Nikolaos, et al.
Publicado: (2021)

Toxic Effects of Antithyroid Drugs
por: Peters, J. P., et al.
Publicado: (1949)

Antithyroid drugs and birth defects
por: Andersen, Stine Linding, et al.
Publicado: (2020)

The effect of prior antithyroid drug use on delaying remission in high uptake Graves' disease following radioiodine ablation
por: Subramanian, Muthiah, et al.
Publicado: (2016)

MON-589 Prognostic Predictors of Initial Response of Graves' Disease to Antithyroid Drugs: A Single Center Experience
por: Alaghoury, Aliaa, et al.
Publicado: (2019)

Cross-sectional investigation of serum creatine kinase concentration in Graves disease patients treated with oral antithyroid drugs
por: Cheng, Ying, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vc68p96hdada14ve4uif6qqk89